Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|July 19, 2014
Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast mediaAna Canga, Maria Kislikova, María Martínez-Gálvez, et al.
Nefrologia|December 28, 2020
Monographic consultation of onconephrology. Rationale and implementationFabiola Alonso, Pilar Auñón, Teresa Cavero, et al.
Current Medical Research and Opinion|May 24, 2007
Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administrationFrancesco Locatelli, Giuseppe Villa, Angel L M de Francisco, et al.
Nefrologia|September 27, 2022
Monographic consultation of onconephrology. Rationale and implementationFabiola Alonso, Pilar Auñón, Teresa Cavero, et al.
Blood Purification|November 13, 2013
Compliance with mineral metabolism targets in haemodialysis patients: moving backwards?I Palomares, R Ramos, A Martin-Malo, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|June 28, 2002
["Occult" renal insufficiency due to evaluating renal function using only serum creatinine]G Fernández-Fresnedo, A L M de Francisco, E Rodrigo, et al.
The Journal of Diabetic Complications|October 1, 1987
The effect of cyclosporine on native renal function in non-uremic diabetic recipients of pancreas transplantsA M De Francisco, S M Mauer, M W Steffes, et al.
Nefrologia|April 2, 2019
Onco-Nephrology: Cancer, chemotherapy and kidneyAngel L M de Francisco, Manuel Macía, Fabiola Alonso, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 3, 2005
Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre studyVíctor Lorenzo, Alejandro Martin-Malo, Rafael Perez-Garcia, et al.
International Journal of Clinical Practice|November 18, 2006
Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II studyA L M de Francisco, W Sulowicz, M Klinger, et al.
Pageof 9